Brenzys (etanercept injection) now indicated for the treatment of plaque psoriasis, psoriatic arthritis and juvenile idiopathic arthritis

15 September 2020 - Brenzys is a biosimilar biologic drug authorised based on its similarity to Enbrel, which is already approved ...

Read more →

Health Canada approves Tremfya (guselkumab injection), a first in class, selective interleukin 23 inhibitor for active psoriatic arthritis

10 September 2020 - Data show Tremfya significantly improved signs and symptoms in joints, skin, and soft tissue of adults with ...

Read more →

Medexus reports Health Canada approval of Gleolan for use in guided surgical resection of high grade gliomas

10 September 2020 - Medexus Pharmaceuticals today announces that on 9 September 2020, it received a Notice of Compliance from ...

Read more →

BeiGene announces acceptance and priority review by Health Canada of new drug submission for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia

9 September 2020 - BeiGene today announced that its new drug submission for Brukinsa (zanubrutinib) for the treatment of patients with ...

Read more →

Canada secures deals for up to 114 million doses of potential COVID-19 vaccines from U.S. drug companies

31 August 2020 - Potential vaccine could be available by spring of next year. ...

Read more →

Health Canada authorises Enspryng for Canadians living with neuromyelitis optica spectrum disorder

31 August 2020 - Roche Canada announced today that Health Canada has granted market authorisation for Enspryng (satralizumab) as monotherapy ...

Read more →

KYE Pharmaceuticals and Catalyst Pharmaceuticals challenge Health Canada’s decision to overlook Firdapse data exclusivity

26 August 2020 - Catalyst Pharmaceuticals and KYE Pharmaceuticals today announced the filing of a proceeding in Canadian Federal Court ...

Read more →

Catalyst takes its fight over a rare disease drug to Canada, suing the country’s regulator

26 August 2020 - In unusual battle between two small companies over the market for a rare disease drug has ...

Read more →

Cystic fibrosis drug could reduce severe disease, deaths if made available to Canadians

25 August 2020 - Talia D’Alessio has been living with cystic fibrosis since she was nine months old. ...

Read more →

Knight and TherapeuticsMD announce Health Canada approval of Imvexxy

25 August 2020 - Knight Therapeutics and TherapeuticsMD announced today the approval of Imvexxy by Health Canada. In Canada, Imvexxy is ...

Read more →

Health Canada grants market authorization for Tecentriq in combination with bevacizumab, the first immunotherapy combination treatment, for the most common form of liver cancer

19 August 2020 - Tecentriq in combination with bevacizumab improved overall survival and progression-free survival compared to the previous standard of ...

Read more →

Dupixent (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis

18 August 2020 - First biologic approved in Canada for adults with severe chronic rhinosinusitis with nasal polyposis. ...

Read more →

Piqray is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR positive, HER2 negative advanced breast cancer

13 August 2020 - Approval is based on results from SOLAR-1, where Piqray in combination with fulvestrant nearly doubled median progression-free ...

Read more →

Elusys Therapeutics receives Health Canada approval for Anthim for the treatment of inhalation anthrax

12 August 2020 - Elusys Therapeutics today announced that Health Canada has approved the company's new drug submission for Anthim ...

Read more →

Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy for the treatment of metastatic non-small cell lung cancer

11 August 2020 - CheckMate-9LA trial results demonstrated superior overall survival versus chemotherapy, regardless of PD-L1 expression or tumour histology. ...

Read more →